Skip Navigation
Skip to contents
Results by Year

View Wide

Filter

ARTICLE TYPE

more+
SELECT FILTER
 
Close

PUBLICATION DATE

13 results
Display

A Case Report of Multiple Capillary Hemangioma in a Chronic Myeloid Leukemia Patient Taking Tyrosine Kinase Inhibitors

Byun HJ, Jang D, Lee J, Oh SJ, Lim Y, Park JH, Lee JH, Lee DY

A capillary hemangioma is a vascular tumor with small capillary sized vascular channel. Multiple capillary hemangioma in relation with drugs have been rarely reported. Here in, we report a case...
CITED
export Copy
Close
SHARE
Twitter Facebook
Close
Dasatinib Inhibits Lyn and Fyn Src-Family Kinases in Mast Cells to Suppress Type I Hypersensitivity in Mice

Lee D, Park YH, Lee JE, Kim HS, Min KY, Jo MG, Kim HS, Choi WS, Kim YM

Mast cells (MCs) are systemically distributed and secrete several allergic mediators such as histamine and leukotrienes to cause type I hypersensitivity. Dasatinib is a type of anti-cancer agent and it...
CITED
export Copy
Close
SHARE
Twitter Facebook
Close
Impact of imatinib or dasatinib coadministration on in vitro preantral follicle development and oocyte acquisition in cyclophosphamide-treated mice

Hong YH, Kim SJ, Kim SK, Lee SC, Jun JH, Jee BC, Kim SH

Objective: We investigated the impact of tyrosine kinase inhibitor (imatinib or dasatinib) coadministration with cyclophosphamide (Cp) on preantral follicle development in an in vitro mouse model. Methods: Seventy-three female BDF1 mice...
CITED
export Copy
Close
SHARE
Twitter Facebook
Close
Depigmentation in a Patient with Chronic Myeloid Leukemia during Chemotherapy with Dasatinib

Choi YW, Na N, Park J

  • KMID: 2451599
  • Korean J Dermatol.
  • 2019 Jun;57(5):292-293.
No abstract available.
CITED
export Copy
Close
SHARE
Twitter Facebook
Close
Dasatinib (Sprycel®)-Associated Acneiform Eruption Improved by Dose Reduction due to Pleural Effusion in a Patient with Chronic Myeloid Leukemia

Lim JH, Woo Y, Kim M, Park HJ

  • KMID: 2436860
  • Korean J Dermatol.
  • 2018 Aug;56(7):472-474.
No abstract available.
CITED
export Copy
Close
SHARE
Twitter Facebook
Close
Cytomegalovirus Colitis during Dasatinib Treatment for Patients with Hematologic Malignancy: Case Series and Literature Review

Choi JK, Cho SY, Choi SM, Kim GH, Lee SE, Lee S, Kim DW, Lee DG

Dasatinib, a tyrosine kinase inhibitor, is widely used for patients with chronic myeloid leukemia and Philadelphia chromosome-positive acute lymphoblastic leukemia. Although the drug has a potent immunosuppressive effect, infectious complications...
CITED
export Copy
Close
SHARE
Twitter Facebook
Close
Dasatinib induces severe hemorrhagic colitis in a patient with accelerated phase of chronic myelogenous leukemia

Yim E, Choi YG, Nam YJ, Lee J, Kim JA

No abstract available.
CITED
export Copy
Close
SHARE
Twitter Facebook
Close
A Case of Chronic Myeloid Leukemia with Multiple Chloromas Treated Successfully with Dasatinib

Jang WY, Choi SM, Park MS, Ahn BC, Heo MH, Kim JY, Kwon KY, Do YR

Chronic myeloid leukemia (CML) is a clonal myeloproliferative disorder of the primitive hematopoietic stem cells. CML is characterized by the overproduction of myeloid cells, which results in marked splenomegaly and...
CITED
export Copy
Close
SHARE
Twitter Facebook
Close
Reversible Pulmonary Arterial Hypertension Associated with Dasatinib for Chronic Myeloid Leukemia

Hong JH, Lee SE, Choi SY, Kim SH, Jang EJ, Bang JH, Park JE, Jeon HR, Oh YJ, Yi JE, Jung HO, Youn HJ, Kim DW

We describe two cases of pulmonary arterial hypertension (PAH) that occurred under dasatinib treatment and were resolved after dasatinib discontinuation. Two patients with chronic phase chronic myeloid leukemia (CML) were...
CITED
export Copy
Close
SHARE
Twitter Facebook
Close
Development of Tyrosine Kinase Inhibitor in Chronic Myeloid Leukemia

Kim H

Chronic myeloid leukemia (CML) is a malignant disease induced by the oncogenic signal of the BCRABL transcript resulting from the translocation between chromosome 9 and 22, t (9:22). This genetic...
CITED
export Copy
Close
SHARE
Twitter Facebook
Close
Recent Advances of Management for Chronic Myeloid Leukemia

Kim DW

  • KMID: 2264772
  • Korean J Med.
  • 2012 Dec;83(6):718-723.
The clinical outcome for patients with chronic myeloid leukemia (CML) has improved radically in the past 15 years. Imatinib led to high rates of complete cytogenetic responses and improved survival...
CITED
export Copy
Close
SHARE
Twitter Facebook
Close
Recent advances in the path toward the cure for chronic myeloid leukemia

Kim DW

Through the phase 3 International Randomized Study of Interferon vs. STI571 (IRIS) trial, imatinib emerged as the standard treatment for chronic myeloid leukemia (CML) and has successfully prolonged the duration...
CITED
export Copy
Close
SHARE
Twitter Facebook
Close
Coexisting with Clonal Evolution and BCR-ABL Mutant in CML Patients Treated with Second-generation Tyrosine Kinase Inhibitors Predict the Discrepancy of in vitro Drug Sensitivity

Ahn JS, Kim YK, Lee SR, Yu L, Yang DH, Cho SH, Shim HJ, Bae WK, Lee JJ, Chung IJ, Shin MG, Kim HJ

  • KMID: 2165975
  • Cancer Res Treat.
  • 2010 Mar;42(1):37-41.
PURPOSE: Second-generation tyrosine kinase inhibitors (second TKIs) such as nilotinib and dasatinib control the activity of most ABL kinase domain mutations observed in patients with imatinib resistance. Although in vitro...
CITED
export Copy
Close
SHARE
Twitter Facebook
Close

Go to Top

Copyright © 2021 by Korean Association of Medical Journal Editors. All rights reserved.     E-mail: koreamed@kamje.or.kr